CN101961504A - Gel coating accessory capable of preventing spinal surgery cerebrospinal fluid leakage - Google Patents
Gel coating accessory capable of preventing spinal surgery cerebrospinal fluid leakage Download PDFInfo
- Publication number
- CN101961504A CN101961504A CN201010253842XA CN201010253842A CN101961504A CN 101961504 A CN101961504 A CN 101961504A CN 201010253842X A CN201010253842X A CN 201010253842XA CN 201010253842 A CN201010253842 A CN 201010253842A CN 101961504 A CN101961504 A CN 101961504A
- Authority
- CN
- China
- Prior art keywords
- fluid
- container
- solid constituent
- buffer solution
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention relates to a gel coating accessory capable of preventing spinal surgery cerebrospinal fluid leakage, comprising a first fluid component in a first buffer solution which contains lysine, dimeric lysine or polylysine and has the pH value of 3-12 in a first container, a second fluid component of a second buffer solution with the pH value of 3-12 in a second container, a combined solid component which is composed of poly (trimethylene carbonate), polylactic acid, polyethylene glycol, polyethylene glycol polytomy isomer, polyurethane, gelatine, polyphosphate, polyglycolic acid and copolymer thereof and blend thereof in a third container as well as a coating tool. Optionally, infusion medicament which is used after spinal surgery can be contained in the first fluid component, the second fluid component and the solid component. When the first fluid component, the second fluid component and the solid component are mixed, gel is formed, and the gel can be directly coated onto the part used for preventing spinal surgery cerebrospinal fluid leakage.
Description
Technical field
The present invention relates to medical instruments field, especially relate to the operation external member of the antiseepage that is used to stop blooding.
Technical background
Surgical operation and wound all can be formed with the blood wound surface, have a large amount of loss of blood therebetween, need in time to adopt the hemostasis means.The absorbable hemostatic material that use has biocompatibility is a kind of common hemostasis means in the hemostasis of blood wound surface is arranged, the time urgent needs is arranged all in the hemostasis of saving oneself of surgery surgical hemostasis, wound, first aid, family, this shows provides the importance of a kind of hemostatic material safe, effective, easy to use and with low cost to human health.Cerebrospinal leak is one of spinal surgery infectious-related complication, and lasting cerebrospinal leak can hinder wound healing, if treat untimely or deal with improperly, can cause injury mouthful do not heal, wound infection, meningitis even spinal canal infection.Symptom and sign has other symptoms such as headache, dizzy, meningismus, low intracranial pressure syndrome, sensory disturbance, causes great misery and inconvenience to the patient.
Existing absorbable hemostatic material commonly used comprises following several:
1, sthptic sponge (SPONGE) class: gelfoam, collagen protein sponge, chitosan sthptic sponge, carboxymethyl cellulose sthptic sponge, contain thrombin or fibrinous sthptic sponge;
2, hemostatic gauze/haemostatic membrane (GAUZE, FILM) class: oxidized cellulose, oxidized regenerated cellulose hemostatic gauze, contain the oxidized cellulose hemostatic gauze of carboxymethyl cellulose;
3, colloid styptic class: Fibrin Glue, synthetic glue;
4, polysaccharide styptic powder class: micropore polysaccharide styptic powder, chitosan styptic powder, algae styptic powder
Below biocompatible hemostatic material commonly used is made a concrete analysis of:
1, absorbability gelfoam and collagen protein sponge
Gelfoam derives from the extract of animal tissue, and its main component is an animal collagen.Its hydrophilic and loose structure be the moisture in the absorbing blood and concentrate blood rapidly, thereby reaches the hemostatic purpose.But gelatin is the collagen extract that derives from animal, contains foreign protein, easily causes allergic reaction, symptom such as can cause that patient generates heat clinically; Simultaneously, human body is slower to the absorption of gelfoam, is generally more than 4 weeks, therefore can increase the infection rate of wound, influences wound healing.Collagen protein sponge also derives from the collagen extract of animal tissue.Except that can be the concentrate blood by the moisture in the absorbing blood, can also be the same with gelfoam by activating intrinsic coagulation mechanism, the raw material sources of collagen protein sponge are in animal, be foreign protein: and human body absorbs slow to it, show as patient allergy reaction clinically, wound healing is slow and the susceptible complication of wound, so clinical use is greatly limited.
2, oxidized cellulose (Oxidized Cellulose), oxidized regenerated cellulose (Oxidized regenerated cellulose) hemostatic gauze
Oxidized cellulose is a kind of of cellulose derivative.Its hemostatic mechanism is that concentrate blood starts clotting mechanism by the characteristic of material suction; Simultaneously, carboxyl combines with Hemoglobin F e, makes blood produce acid haematin, forms brown blob of viscose, and the sealing blood capillary is terminal and stop blooding.Oxidized regenerated cellulose is identical with the hemostatic mechanism of oxidized cellulose.
Oxidized cellulose is a synthetic.Normal tissue is the enzyme of metabolism oxidized cellulose and relatively slow to this series products degradation speed for want of, be at least for 3～6 weeks according to the general time that absorbs in vivo of the position of consumption and use, clinical cause partial infection and influence local organization heal.Publication number CN1533751A discloses a kind of hemostasis wound dressing, commodity are called SURGICEL, comprise fabric and be coated on surface that fabric contacts with wound and be scattered in porous polymer substrate in the fabric to small part, this substrate comprises biocompatible water solublity or water-swellable polymer, and the fiber of fabric is an oxidized regenerated cellulose, and water solublity or water-swellable polymer are polysaccharide.But the main body that this bleeding-stopping dressing is selected for use is the cellulose of oxidation, and absorption of human body is slow, and it organizes adhesive force poor, so clinical practice is restricted.
3, Fibrin Glue (Fibrin glue)
Fibrin Glue is made up of Fibrinogen, thrombin, aprotinin and calcium chloride.Anastalsis mainly is the blood coagulation that the thrombin activation Fibrinogen promotes body.In recent years clinical practice is fibrin sealant comparatively widely, is the mixing arrangement of Fibrinogen and thrombin.Thrombin in the Fibrin Glue and fibrin derive from human body or animal, easily cause the patient allergy reaction, and cause infecting humanized and zoonosis, as hepatitis, acquired immune deficiency syndrome (AIDS), bovine spongiform encephalopathy etc.Fibrin Glue be applied in moistening adhesiveness when organizing wound surface a little less than, can not effectively control active hemorrhage.And albumin glue is difficult for storage and transportation, uses inconvenience.
4, natural biological polysaccharide product
In recent years, the production development of natural biological polysaccharide is rapid, receives publicity.Being used for hemostatic natural biological polysaccharide product at present is plant polysaccharide and chitosan.Their good biocompatibility, nontoxic, non-stimulated, be difficult for causing the anaphylaxis of body, can not cause simultaneously and infect or infection humanized and zoonosis.
(1) chitosan/chitin kind product
The product of chitosan/chitin is representational to be high swollen molten chitosan sponge, is to be that raw material is made with natural marine organism extract chitosan.Chitosan has water absorption preferably, can cause and quicken to start the clotting mechanism of self and therefore coagulant can become the hemorrhage of external.But,, still can't in surgical operation, use owing to lack in the human body with its rapid effectively enzyme of degraded.At present, do not see as yet both at home and abroad its hemostatic material as the III class is used for Clinical Surgery's art hemostatic report.
(2) micropore polysaccharide-(Microporous Polysaccharide Hemospheres, MPH)
2002, a kind of absorbable hemostasia material (U.S. Pat 6060461) that is called AristaTM of the Medafor company research and development of the U.S., its effective ingredient is many micropore polysaccharides, comprises glucosan.This micropore polysaccharide is made by polysaccharide and chloropropylene oxide reaction, and the chloropropylene oxide and the starch molecule effect that have hydroxyl generate the ethyl glycerol, can make glucose molecule be cross-linked into tridimensional network.
Arista
TMHemostatic material exists some problems.At first, from application surface, this hemostatic material mainly still is confined to the hemostasis of skin or soft tissue wound surface, and the hemostasis under the endoscope particularly (as Minimally Invasive Surgerys such as gastroscope, intestinal mirror and peritoneoscopes time) of stopping blooding still lacks effective means to the histoorgan in body cavity deep; The second, on preparation method, chloropropylene oxide is a colourless oil liquid, toxic and narcoticness, and it is unfavorable to environmental protection therefore to produce this product, and production cost is also higher; The 3rd, from haemostatic effect, because its water absorption is strong inadequately, water absorbent rate is low, and the speed of suction is slower, and haemostatic effect is undesirable, and is not good enough to the active hemorrhage haemostatic effect especially; The 4th, its viscosity is low, and the gel viscosity that suction back forms is poor, therefore with the blood effect after the sludged blood that forms and the poor adhesion of tissue, can not produce effective viscosity shutoff to tissue, the blood vessel of breakage, thereby influence the hemostatic effect; The 5th, when active hemorrhage, styptic powder is difficult to easily be washed away by blood flow attached to hemorrhage place, if push with adjuvant on styptic powder, then adjuvant is easy to be caused once more hemorrhage when opening adjuvant by the sludged blood adhesion.Therefore, bad to the active hemorrhage haemostatic effect.
The objective of the invention is to overcome the deficiencies in the prior art, the gel application kit of cerebrospinal fluid seepage behind a kind of new prevented spinal surgery is provided, the employed gel of described external member has favorable biological degradability, biocompatibility, security reliability.
Summary of the invention
In order to finish the foregoing invention purpose, the invention provides a kind of gel application kit that prevents cerebrospinal fluid seepage behind the spinal surgery, described external member comprises:
A) the first fluid component in first container of sealing, described first fluid component comprise that it is the solution that forms in first buffer solution 3 to 12 that the lysine compounds that is selected from the group of being made up of lysine, two polylysines, poly-D-lysine and combination thereof is dissolved in pH value;
B) second fluid components in second container of sealing, described second fluid components is that pH value is second buffer solution between 3 to 12;
C) solid constituent in the 3rd container of sealing, described solid constituent comprises medical macromolecular materials, described medical macromolecular materials are selected from by PTMC, polylactic acid, Polyethylene Glycol, the isomer of Polyethylene Glycol multi-branched, glutin, polyurethane, gelatin, poly phosphate, the group that polyglycolic acid and copolymer thereof and blend are formed, and described medical macromolecular materials have with 1% concentration be dissolved in 25 ℃ the chloroform solvent with Ubbelohde viscometer record 0.01 to 5dl/g, be preferably 0.05 to 0.2dl/g the interior intrinsic viscosity of scope; And
D) coating tool;
And,
Described first fluid component, described second fluid components and described solid constituent constitute the prescription of described gel application kit, gross weight in described prescription, the percentage by weight of described lysine compounds is 0.1%～30%, is preferably 0.1%～10%; The percentage by weight of described medical macromolecular materials is 1%-70%; Volume ratio between described first fluid component and described second fluid components is from 30: 70 to 70: 30, is preferably 40: 60 to 60: 40, more preferably 45: 55 to 55: 45; And, when described first fluid component, described second fluid components and described solid constituent are mixed, form gel jointly.
In some embodiments, described first buffer solution and second buffer solution are selected from phosphate buffer solution and borate buffer solution independently of one another.
In some embodiments, described first buffer solution be pH6 to 12 borate buffers, described second buffer solution is the phosphate buffer solution of pH 3 to 11.
In some embodiments, the weight average molecular weight of described medical macromolecular materials is 1000 to 300,000 dalton, preferably in 2000 to 50,000 scope.
In some embodiments, one or more of described first fluid component, described second fluid components or described solid constituent are planted and also to be comprised and be selected from by hemostasis class medicine, alleviate cellular edema class medicine, antibiotics, antiviral class medicine and the medicine of the group formed, and, in the gross weight of described prescription, the percetage by weight of described medicine is 0.01%～20%.
In some embodiments, described hemostasis class medicine is selected from tranexamic acid and hemocoagulase; The described cellular edema class medicine that alleviates is an aescine; Described antibiotics is selected from penicillin, cephalosporin, vancomycin, tobramycin, amikacin and gentamycin and dexamethasone; Described antiviral class medicine is selected from virazole, acyclovir and ganciclovir.
In some embodiments, described solid constituent is the powder of homogeneous.
In some embodiments, in described first fluid component, described second fluid components and the described solid constituent one or more are planted and are also comprised medical stain, and in the gross weight of described prescription, the percetage by weight of described medical stain is 1: 100～10: 100.
In some embodiments, described coating tool is used for the described solid constituent in described the 3rd container being dissolved into after second fluid components in described second container forms the macromolecular material fluid, the described macromolecular material fluid in first fluid component in described first container and described second container is mixed the position that is coated to cerebrospinal fluid seepage behind the described spinal surgery.
The gel application kit that prevents cerebrospinal fluid seepage behind the spinal surgery provided by the present invention, spinal dura mater is coated on wound surface after sewing up when the clinical spinal operation of doctor, favorable biological degradability, biocompatibility, the security reliability of utilizing this colloidal material itself to possess, prevent postoperative because cerebrospinal fluid oozes out the adverse events such as infection of initiation, and, when described gel carries medicine, can slowly discharge medicine, reduce or avoid seepage to take place and promote wound healing.This product is transparent colloid when using, and can be hydrolyzed in 1 year, metabolism goes out external.It is crosslinked its terminal double bond to be formed two or more fluids mixing by blender during use, seals the tissue site of oozing of blood sepage, thereby reaches the purpose of hemostasis antiseepage.
Description of drawings
Fig. 1 is the sketch map that prevents the gel application kit of cerebrospinal fluid seepage behind the spinal surgery of the present invention.
Fig. 2 is the gel application kit sketch map in use that prevents cerebrospinal fluid seepage behind the spinal surgery of the present invention.
The specific embodiment
As shown in Figure 1, provided by the present invention prevent spinal surgery after the gel application kit 100 of cerebrospinal fluid seepage comprise the first fluid component 11 that is carried in first container 10, be carried on second fluid components 21 in second container 20, be carried on solid constituent 31 and coating tool 40 in the 3rd container 30.During use, described solid constituent 31 in described the 3rd container 30 is dissolved into after second fluid components 21 in described second container 20 forms the macromolecular material fluids, the described macromolecular material fluid in first fluid component 11 in described first container 10 and described second container 20 is formed gel by mixing.By means of coating tool 40, the gel that forms can be applied directly to the position of cerebrospinal fluid seepage behind the spinal surgery.
In first fluid component 11, the lysine compounds is selected from the group that lysine, two polylysines, poly-D-lysine and combination are formed, wherein, and preferred two polylysines or three polylysines.The lysine compounds accounts for 0.1%～30% of described prescription gross weight, is preferably 0.1%～10%.
In the first fluid component 11 is that first buffer solution between 3 to 12 is generally phosphate buffer solution or borate buffer solution at pH value, also can use other medical buffer solution commonly used.Preferably, first buffer solution is the borate buffer of pH 6 to 12.
Described first fluid component 11 seals preservation in first container 10.
Described second fluid components 21 is generally phosphate buffer solution or borate buffer solution for pH value is second buffer solution between 3 to 12, also can use other medical buffer solution commonly used.Described second buffer solution can be identical or different with first buffer solution in the first fluid component 11.Preferably, second buffer solution is the phosphate buffer of pH 3 to 11.
Described second fluid components 21, perhaps alternatively, described second fluid components 21 that is used for the infusion medicament medicine behind the spinal surgery that comprises is preserved in 20 sealings of second container.
The volume of described first fluid component 11 and described second fluid components 21 can be identical or different, and volume ratio between the two was preferably 40: 60 to 60: 40 from 30: 70 to 70: 30, more preferably 45: 55 to 55: 45.For easy to use, both volumes are substantially the same.
Described solid constituent 31 seals preservation in the 3rd container 30.Described solid constituent 31 comprises medical macromolecular materials, described medical macromolecular materials comprise the homogenous material, the copolymer between two or more of PTMC and PLA copolymer, Polyethylene Glycol and multi-branched isomer thereof, glutin, polyurethane, gelatin, poly phosphate, polyglycolic acid or in the blend any one, and its copolymerization or blend weight ratio are all 1%: 99%-99%: in 1% scope.Its intrinsic viscosity of its blend or copolymer (dark type viscometer, chloroform solvent 1% concentration, 25 ℃) scope is the wherein best 0.05-0.2dl/g of being of 0.01-5dl/g.; Weight average molecular weight range is 1000-300000 dalton, and wherein the best is 2000-50000 dalton.
In the gross weight of described prescription, the percentage by weight of described medical macromolecular materials is 1%-70%.
Described gel application kit can also comprise the infusion medicament medicine that is used for behind the spinal surgery, and described medicine is selected from 1, the hemostasis class: tranexamic acid, hemocoagulase; 2, alleviate the cellular edema class: aescine; 3, antibiotics: penicillin, cephalosporin, vancomycin, tobramycin, amikacin, gentamycin and dexamethasone; 4, antiviral class: any or its combination in virazole, acyclovir and the ganciclovir etc.In view of the consideration to selected medicine stability, described medicine can be included in described first fluid component 11, described second fluid components 21 or the described solid constituent 31.Certainly, described medicine can also can be present in the 4th container (not shown) of sealing individually.Preferably, the described infusion medicament medicine that is used for behind the spinal surgery be by with its any one or its combination be dissolved in phosphate buffer solution or the borate buffer solution of pH value between 3 to 12 and form.In the gross weight of described prescription, the percetage by weight of described medicine is 0.01%～20%.According to selected stability of drug, those skilled in the art can determine that any in above three kinds of components or which described medicine be present in by the method for routine.Usually, described drug component is present in second fluid components.
Described gel application kit also comprises medical stain, and described medical stain can be one or more, is used for indicating each component of gel application kit, preparation before being convenient to apply and application subsequently.Described medical stain can be included in during in described first fluid component 11, described second fluid components 21 and the described solid constituent 31 one or more plant.Described medical stain can be the stain of using always that is used for medicine, makes before the preparation or one of described first fluid component 11, described second fluid components 21 or described solid constituent 31 after the preparation or wherein two kinds or all present as colors such as red, orange, yellow, green, blue or green, blue, purples.In the gross weight of described prescription, the percetage by weight of described medical stain is 0.01%～5%.
Described coating tool 40 has been used in the dissolving that will draw back second container 20 again the macromolecular material fluid of solid constituent 31 to be mixed with the first fluid component 11 in first container, and is coated to the position of cerebrospinal fluid seepage behind the described spinal surgery.
Preferably, described coating tool 40 comprises two or more syringes, multi-syringe pushing ram binding frame, threeway or leads to hybrid junctioin and atomizer more.As shown in Figure 2, two syringes 410 and 420 and can distinguish directly as described first container 10 and second container 20 are used for carrying respectively described first fluid component 11 and described second fluid components 21.After with syringe 420 second fluid components 21 being injected the 3rd container 30, dissolving described solid constituent 31, the macromolecular material fluid 22 that has dissolved solid constituent 31 is drawn back in the syringe 420 again.Atomizer 450 and multi-syringe pushing ram binding frame 460 by means of threeway hybrid junctioin 440 and front end thereof, first fluid component 11 and macromolecular material fluid 22 fully can be mixed formation gel 70 in back by means of promoting multi-syringe pushing ram binding frame 460 through threeway hybrid junctioin 440 and atomizer 450, described gel 70 can be applied directly to the position (not shown) that is coated to cerebrospinal fluid seepage behind the described spinal surgery.
Syringe 410,420 is shaped as cylindrical cuboid or polygon, syringe 410,420, multi-syringe pushing ram binding frame 460, threeway or how the material of logical hybrid junctioin 440 and atomizer 450 be medical glass or medical plastic.
Included coating tool is not limited to above-mentioned form in the gel application kit of the present invention, other, also can use such as utilizing manual mixing to form the instrument that applies again behind the gel, to finish the present invention.
Of the present inventionly prevent that the gel application kit of cerebrospinal fluid seepage behind the spinal surgery can be according to the conventional method preparation of this area, for instance, described external member can prepare according to following steps.
The macromolecule medical material through after grinding homogenizing, is added medical stain and/or medicine alternatively, make the solid constituent 31 of homogeneous particle diameter powder, such material uses for many years at clinical safety, is a kind of safe material that can be implanted at human body.With artificial after the accurate weighing of materials mixed or the equipment vacuum seal in the bottle (the 3rd container 30) of packing into automatically.
Prepare the first fluid component 11 and second fluid components 21 respectively, afterwards, artificial respectively or canned in first container 10 and second container 20 automatically, preferably, described first container 10 and second container 20 are formed the form of syringe, and promptly syringe 410,420, respectively sealing.
With first container 10, second container 20 and the 3rd container 30, together with after coating tool 40 packing through irradiation or gaseous sterilization.
Front opening packing to be used, second fluid components 21 in second container 20 is injected the solid constituent 31 of the 3rd container 30, to be mixedly draw back second container 20 after evenly, when first container 10 and second container 20 are the container of syringe form, two syringes 410,420 can be tied on the shelf 460 simultaneously, load onto threeway hybrid junctioin 440 at the syringe front end, and after the port of export of described threeway hybrid junctioin 440 is installed nozzle 450, advance the injection rod of two syringes simultaneously.Mix when two or more solution process blenders and nozzle and the rapid cross-linking reaction that forms, just after contacting tissue, form gelinite.
The pH value of mixed gel solution 70 is between 6 to 9, and gelation rate is between 1 second to 30 seconds.The degradation time of final gelatinous mass is 1 week to 1 year.The medicament slow release time of final gelatinous mass is 3 days to 180 days.
Below come detailed presentations the present invention by specific embodiment.Need to prove that disclosed specific embodiment only is used for illustrating the present invention, rather than is used for limiting claimed scope of the present invention.The scope of protection of present invention is specifically limited by claim.
Each element of coating tool is made by the inventor, and material is a medical plastic.
Embodiment 1
The gel application kit:
1) first fluid component: (pH 6 for the borate buffer of poly-D-lysine (0.1g); 5ml);
2) second fluid components: (pH 11 for phosphate buffer; 5ml), wherein be dissolved with dexamethasone (0.1g);
3) solid constituent: PTMC and PLA copolymer (2g; Weight average molecular weight 12KD);
4) coated tool: (as shown in Figure 2).
Preparation: be 6 5ml borate buffer in pH value earlier with 0.1g poly-D-lysine powder dissolution, again with 0.1g dexamethasone powder dissolution in pH value is 11 5ml phosphate buffer, and respectively fill in two syringes 410 and 420; The PTMC of weighing 2g weight average molecular weight 12KD and PLA copolymer powder are loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, simultaneously two syringes 410 and 420 front ends install additional and inject two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 2:
The gel application kit:
1) first fluid component: (pH 10 for the borate buffer of poly-D-lysine (0.04g); 2ml);
2) second fluid components: (pH 4 for phosphate buffer; 5ml);
3) solid constituent: Polyethylene Glycol multi-branched isomer (0.7g; Weight average molecular weight 30KD);
4) coated tool: (as shown in Figure 2).
Preparation: being 10 2ml borate buffer with 0.04g poly-D-lysine powder dissolution in pH value earlier, is 4 5ml phosphate buffer again with pH value, and fill is in two syringes 410 and 420 respectively; The Polyethylene Glycol multi-branched isomer powder of weighing 0.7g weight average molecular weight 30KD is loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, simultaneously two syringes 410 and 420 front ends install additional and inject two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 3:
The gel application kit:
1) first fluid component: (pH 12 for the borate buffer of two polylysines (0.2g); 5ml);
2) second fluid components: (pH 3 for phosphate buffer; 5ml);
3) solid constituent: gelatin (0.1g) and glutin (1g; Weight average molecular weight 30KD);
4) coated tool: (as shown in Figure 2).
Preparation: earlier 0.2g dimerization lysine powder being dissolved in pH value and being 12 5ml borate buffer, is 3 5ml phosphate buffer again with pH value, and fill is in two syringes 410 and 420 respectively; Weighing 0.1g gelatin powder and 1g weight average molecular weight 30KD glutin powder are loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, two syringes 410 and 420 front ends install additional injects two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 4:
The gel application kit:
1) first fluid component: (pH 8 for the borate buffer of poly-D-lysine (0.5g); 5ml);
2) second fluid components: (pH 5 for phosphate buffer; 5ml), wherein be dissolved with cephamycin (0.01g);
3) solid constituent: polyglycolic acid (5g; Weight average molecular weight 8KD);
4) coated tool: (as shown in Figure 2).
Preparation: be 8 5ml borate buffer in pH value earlier with 0.5g poly-D-lysine powder dissolution, again with 0.01g cephamycin powder dissolution in pH value is 5 5ml phosphate buffer, and respectively fill in two syringes 410 and 420; The polyglycolic acid powder of weighing 5g weight average molecular weight 8KD is loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, two syringes 410 and 420 front ends install additional injects two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 5:
The gel application kit:
1) first fluid component: (pH 7 for the borate buffer of poly-D-lysine (0.01g); 3ml);
2) second fluid components: (pH 7 for phosphate buffer; 3ml);
3) solid constituent: poly phosphate (0.01g; Weight average molecular weight 80KD);
4) coated tool (as shown in Figure 2).
Preparation: being 7 3ml borate buffer with 0.01g poly-D-lysine powder dissolution in pH value earlier, is 7 3ml phosphate buffer again with pH value, and fill is in two syringes 410 and 420 respectively; The poly phosphate powder of weighing 0.01g weight average molecular weight 80KD is loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, two syringes 410 and 420 front ends install additional injects two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 6:
The gel application kit:
1) first fluid component: (pH 11 for the borate buffer of poly-D-lysine (0.001g); 1ml);
2) second fluid components: (pH 4.5 for phosphate buffer; 1ml), wherein be dissolved with dexamethasone (0.01g);
3) solid constituent: Polyethylene Glycol multiple-limb isomer (0.2g; Weight average molecular weight 5KD);
4) coated tool: (as shown in Figure 2).
Preparation: be 11 1ml borate buffer in pH value earlier with 0.001g poly-D-lysine powder dissolution, again with 0.01g dexamethasone powder dissolution in pH value is 4.5 1ml phosphate buffer, and respectively fill in two syringes 410 and 420; The Polyethylene Glycol multiple-limb isomer powder of weighing 0.2g weight average molecular weight 5KD is loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use; Before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, two syringes 410 and 420 front ends install additional injects two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 7:
The gel application kit:
1) first fluid component: (pH 12 for the borate buffer of poly-D-lysine (0.15g); 1ml);
2) second fluid components: (pH 3 for phosphate buffer; 1ml), wherein be dissolved with hemocoagulase (0.5g);
3) solid constituent: polyurethane (3g; Weight average molecular weight 5KD);
4) coated tool: (as shown in Figure 2).
Preparation: be 12 1ml borate buffer in pH value earlier with 0.15g poly-D-lysine powder dissolution, again with 0.5g hemocoagulase powder dissolution in pH value is 3 1ml phosphate buffer, and respectively fill in two syringes 410 and 420; The polyurethane powder of weighing 3g weight average molecular weight 5KD is loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, two syringes 410 and 420 front ends install additional injects two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 8:
The gel application kit:
1) first fluid component: (pH 9 for the borate buffer of poly-D-lysine (0.6g); 5ml);
2) second fluid components: (pH 5 for phosphate buffer; 5ml), wherein be dissolved with acyclovir (0.1g);
3) solid constituent: PTMC and PLA copolymer (1.5g; Weight average molecular weight 32KD);
4) coated tool: (as shown in Figure 2).
Preparation: be 9 5ml borate buffer in pH value earlier with 0.6g poly-D-lysine powder dissolution, again with 0.1g acyclovir powder dissolution in pH value is 5 5ml phosphate buffer, and respectively fill in two syringes 410 and 420; The PTMC of weighing 1.5g weight average molecular weight 32KD and PLA copolymer powder are loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, two syringes 410 and 420 front ends install additional injects two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 9:
The gel application kit:
1) first fluid component: (pH 11 for the borate buffer of poly-D-lysine (0.06g); 2ml);
2) second fluid components: (pH 4.5 for phosphate buffer; 5ml);
3) solid constituent: Polyethylene Glycol multi-branched isomer (1g; Weight average molecular weight 15KD);
4) coated tool: (as shown in Figure 2).
Preparation: being 11 2ml borate buffer with 0.06g poly-D-lysine powder dissolution in pH value earlier, is 4.5 5ml phosphate buffer again with pH value, and fill is in two syringes 410 and 420 respectively; The Polyethylene Glycol multi-branched isomer powder of weighing 1g weight average molecular weight 15KD is loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, simultaneously two syringes 410 and 420 front ends install additional and inject two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 10:
The gel application kit:
1) first fluid component: (pH 7 for the borate buffer of poly-D-lysine (0.5g); 5ml);
2) second fluid components: (pH 8 for phosphate buffer; 5ml);
3) solid constituent: polyglycolic acid (5g; Weight average molecular weight 58KD);
4) coated tool: (as shown in Figure 2).
Preparation: being 7 5ml borate buffer with 0.5g poly-D-lysine powder dissolution in pH value earlier, is 8 5ml phosphate buffer again with pH value, and fill is in two syringes 410 and 420 respectively; The polyglycolic acid powder of weighing 5g weight average molecular weight 58KD is loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, two syringes 410 and 420 front ends install additional injects two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 11:
The gel application kit:
1) first fluid component: (pH 12 for the borate buffer of poly-D-lysine (1g); 5ml);
2) second fluid components: (pH 11 for phosphate buffer; 5ml), wherein be dissolved with dexamethasone (0.1g) and medical stain (0.1mg);
3) solid constituent: PTMC and PLA copolymer (2g; Weight average molecular weight 12KD);
4) coated tool: (as shown in Figure 2).
Preparation: be 12 5ml borate buffer in pH value earlier, again 0.1g dexamethasone powder, the medical stain of 0.1mg be dissolved in pH value and be in 11 the 5ml phosphate buffer 1g poly-D-lysine powder dissolution, and respectively fill in two syringes 410 and 420; The PTMC of weighing 2g weight average molecular weight 12KD and PLA copolymer powder are loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, simultaneously two syringes 410 and 420 front ends install additional and inject two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 12:
The gel application kit:
1) first fluid component: (pH 10 for the borate buffer of poly-D-lysine (0.01g); 2ml);
2) second fluid components: (pH 3 for phosphate buffer; 5ml), wherein be dissolved with medical stain (0.01mg);
3) solid constituent: Polyethylene Glycol multi-branched isomer (0.5g; Weight average molecular weight 10KD);
4) coated tool: (as shown in Figure 2).
Preparation: be 10 2ml borate buffer in pH value earlier, the more medical stain of 0.01mg be dissolved in pH value and be 3 5ml phosphate buffer 0.01g poly-D-lysine powder dissolution, and respectively fill in two syringes 410 and 420; The Polyethylene Glycol multi-branched isomer powder of weighing 0.5g weight average molecular weight 10KD is loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, simultaneously two syringes 410 and 420 front ends install additional and inject two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 13:
The gel application kit:
1) first fluid component: (pH 6 for the borate buffer of two polylysines (0.002g); 5ml);
2) second fluid components: (pH 7.3 for phosphate buffer; 5ml), wherein be dissolved with medical stain (0.001mg);
3) solid constituent: gelatin (0.01g) and glutin (3g; Weight average molecular weight 9KD);
4) coated tool: (as shown in Figure 2).
Preparation: earlier 0.002g dimerization lysine powder is dissolved in pH value and is 6 5ml borate buffer, the more medical stain of 0.001mg is dissolved in pH value and is in 7.3 the 5ml phosphate buffer, and respectively fill in two syringes 410 and 420; Weighing 0.01g gelatin powder and 3g weight average molecular weight 9KD glutin powder are loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, two syringes 410 and 420 front ends install additional injects two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 14:
The gel application kit:
1) first fluid component: (pH 9 for the borate buffer of poly-D-lysine (0.55g); 5ml);
2) second fluid components: (pH 3.6 for phosphate buffer; 5ml), wherein be dissolved with medical stain (0.1mg);
3) solid constituent: polyglycolic acid (5g; Weight average molecular weight 50KD);
4) coated tool: (as shown in Figure 2).
Preparation: be 9 5ml borate buffer in pH value earlier, the more medical stain of 0.1mg be dissolved in pH value and be in 3.6 the 5ml phosphate buffer 0.55g poly-D-lysine powder dissolution, and respectively fill in two syringes 410 and 420; The polyglycolic acid powder of weighing 5g weight average molecular weight 50KD is loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, two syringes 410 and 420 front ends install additional injects two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 15:
The gel application kit:
1) first fluid component: (pH 11 for the borate buffer of poly-D-lysine (0.1g); 3ml);
2) second fluid components: (pH 4 for phosphate buffer; 3ml), wherein be dissolved with medical stain (0.01mg);
3) solid constituent: poly phosphate (1g; Weight average molecular weight 10KD);
4) coated tool: (as shown in Figure 2).
Preparation: be 11 3ml borate buffer in pH value earlier, the more medical stain of 0.01mg be dissolved in pH value and be in 4 the 3ml phosphate buffer 0.1g poly-D-lysine powder dissolution, and respectively fill in two syringes 410 and 420; The poly phosphate powder of weighing 1g weight average molecular weight 10KD is loaded in the 3rd container 30; The configuration coated tool; Pack; Through irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, two syringes 410 and 420 front ends install additional injects two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 16:
The gel application kit:
1) first fluid component: (pH 9 for the borate buffer of poly-D-lysine (0.05g); 1ml);
2) second fluid components: (pH 4 for phosphate buffer; 1ml), wherein be dissolved with medical stain (0.001mg);
3) solid constituent: Polyethylene Glycol multiple-limb isomer (0.5g; Weight average molecular weight 20KD);
4) coated tool: (as shown in Figure 2).
Preparation: be 9 1ml borate buffer in pH value earlier, the more medical stain of 0.001mg be dissolved in pH value and be in 4 the 1ml phosphate buffer 0.05g poly-D-lysine powder dissolution, and respectively fill in two syringes 410 and 420; The Polyethylene Glycol multiple-limb isomer powder of weighing 0.5g weight average molecular weight 20KD is loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, two syringes 410 and 420 front ends install additional injects two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 17:
The gel application kit:
1) first fluid component: (pH 7 for the borate buffer of poly-D-lysine (0.015g); 1ml);
2) second fluid components: (pH 6 for phosphate buffer; 1ml), wherein be dissolved with medical stain (0.1mg);
3) solid constituent: polyurethane (1g; Weight average molecular weight 15KD);
4) coated tool: (as shown in Figure 2).
Preparation: be 7 1ml borate buffer in pH value earlier, the more medical stain of 0.1mg be dissolved in pH value and be in 6 the 1ml phosphate buffer 0.015g poly-D-lysine powder dissolution, and respectively fill in two syringes 410 and 420; The polyurethane powder of weighing 1g weight average molecular weight 15KD is loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, two syringes 410 and 420 front ends install additional injects two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 18:
The gel application kit:
1) first fluid component: (pH 11 for the borate buffer of poly-D-lysine (0.06g); 5ml);
2) second fluid components: (pH 3 for phosphate buffer; 5ml), wherein be dissolved with medical stain (0.01mg);
3) solid constituent: PTMC and PLA copolymer (3.5g; Weight average molecular weight 11KD);
4) coated tool: (as shown in Figure 2).
Preparation: be 11 5ml borate buffer in pH value earlier, the more medical stain of 0.01mg be dissolved in pH value and be in 3 the 5ml phosphate buffer 0.06g poly-D-lysine powder dissolution, and respectively fill in two syringes 410 and 420; The PTMC of weighing 3.5g weight average molecular weight 11KD and PLA copolymer powder are loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, two syringes 410 and 420 front ends install additional injects two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 19:
The gel application kit:
1) first fluid component: (pH 9 for the borate buffer of poly-D-lysine (0.02g); 2ml);
2) second fluid components: (pH 3.5 for phosphate buffer; 5ml), wherein be dissolved with medical stain (0.01mg);
3) solid constituent: Polyethylene Glycol multi-branched isomer (1g; Weight average molecular weight 25KD);
4) coated tool: (as shown in Figure 2).
Preparation: be 9 2ml borate buffer in pH value earlier, the more medical stain of 0.01mg be dissolved in pH value and be 3.5 5ml phosphate buffer 0.02g poly-D-lysine powder dissolution, and respectively fill in two syringes 410 and 420; The Polyethylene Glycol multi-branched isomer powder of weighing 1g weight average molecular weight 25KD is loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, simultaneously two syringes 410 and 420 front ends install additional and inject two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Embodiment 20:
The gel application kit:
1) first fluid component: (pH 10 for the borate buffer of poly-D-lysine (0.005g); 5ml);
2) second fluid components: (pH 4 for phosphate buffer; 5ml), wherein be dissolved with medical stain (0.01mg);
3) solid constituent: polyglycolic acid (1g; Weight average molecular weight 18KD);
4) coated tool: (as shown in Figure 2).
Preparation: be 10 5ml borate buffer in pH value earlier, the more medical stain of 0.01mg be dissolved in pH value and be in 4 the 5ml phosphate buffer 0.005g poly-D-lysine powder dissolution, and respectively fill in two syringes 410 and 420; The polyglycolic acid powder of weighing 1g weight average molecular weight 18KD is loaded in the 3rd container 30; The configuration coated tool; Pack; Irradiation sterilization;
Use: before use the solid constituent 31 in the 3rd container 30 is dissolved in second fluid components 21 in the syringe 420, two syringes 410 and 420 front ends install additional injects two kinds of liquid simultaneously behind threeway and the nozzle it is mixed rapidly at the nozzle place, form gel after being sprayed at wound, final wound closure.
Claims (10)
1. gel application kit that can prevent cerebrospinal fluid seepage behind the spinal surgery, described external member comprises:
A) the first fluid component in first container of sealing, described first fluid component comprise that it is the solution that forms in first buffer solution 3 to 12 that the lysine compounds that is selected from the group of being made up of lysine, two polylysines, poly-D-lysine and combination thereof is dissolved in pH value;
B) second fluid components in second container of sealing, described second fluid components is that pH value is second buffer solution between 3 to 12;
C) solid constituent in the 3rd container of sealing, described solid constituent comprises medical macromolecular materials, described medical macromolecular materials are selected from by PTMC, polylactic acid, Polyethylene Glycol, the isomer of Polyethylene Glycol multi-branched, glutin, polyurethane, gelatin, poly phosphate, the group that polyglycolic acid and copolymer thereof and blend are formed, and described medical macromolecular materials have with 1% concentration be dissolved in 25 ℃ the chloroform solvent with Ubbelohde viscometer record 0.01 to 5dl/g, be preferably 0.05 to 0.2dl/g the interior intrinsic viscosity of scope; And
D) coating tool;
And,
Described first fluid component, described second fluid components and described solid constituent constitute the prescription of described gel application kit, gross weight in described prescription, the percentage by weight of described lysine compounds is 0.1%～30%, is preferably 0.1%～10%; The percentage by weight of described medical macromolecular materials is 1%-70%; Volume ratio between described first fluid component and described second fluid components is from 30: 70 to 70: 30, is preferably 40: 60 to 60: 40, more preferably 45: 55 to 55: 45; And, when described first fluid component, described second fluid components and described solid constituent are mixed, form gel jointly.
2. gel application kit as claimed in claim 1, wherein, described first buffer solution and second buffer solution are selected from phosphate buffer solution and borate buffer solution independently of one another.
3. gel application kit as claimed in claim 1, wherein, described first buffer solution is pH 6 to 12 borate buffers; Described second buffer solution is the phosphate buffer solution of pH 3 to 11.
4. gel application kit as claimed in claim 1, the weight average molecular weight of wherein said medical macromolecular materials is in 1000 to 300,000 daltonian scopes.
5. gel application kit as claimed in claim 4, the weight average molecular weight of wherein said medical macromolecular materials is in 2000 to 50,000 daltonian scopes.
6. gel application kit as claimed in claim 1, one or more of wherein said first fluid component, described second fluid components or described solid constituent are planted and also to be comprised and be selected from by hemostasis class medicine, alleviate cellular edema class medicine, antibiotics, antiviral class medicine and the medicine of the group formed, and, in the gross weight of described prescription, described drug weight percentage ratio is 0.01%～20%.
7. gel application kit as claimed in claim 6, wherein said hemostasis class medicine is selected from tranexamic acid and hemocoagulase; The described cellular edema class medicine that alleviates is an aescine; Described antibiotics is selected from penicillin, cephalosporin, vancomycin, tobramycin, amikacin, gentamycin and dexamethasone; Described antiviral class medicine is selected from virazole, acyclovir and ganciclovir.
8. gel application kit as claimed in claim 1, wherein said solid constituent are the powder of homogeneous.
9. gel application kit as claimed in claim 1, in wherein said first fluid component, described second fluid components and the described solid constituent one or more are planted and are also comprised medical stain, and, in the gross weight of described prescription, the percetage by weight of described medical stain is 1: 100～10: 100.
10. gel application kit as claimed in claim 1, wherein said coating tool is used for the described solid constituent in described the 3rd container being dissolved into after second fluid components in described second container forms the macromolecular material fluid, the described macromolecular material fluid in first fluid component in described first container and described second container is mixed the position that is coated to cerebrospinal fluid seepage behind the described spinal surgery.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010253842.XA CN101961504B (en) | 2010-08-13 | 2010-08-13 | Gel coating accessory capable of preventing spinal surgery cerebrospinal fluid leakage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010253842.XA CN101961504B (en) | 2010-08-13 | 2010-08-13 | Gel coating accessory capable of preventing spinal surgery cerebrospinal fluid leakage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101961504A true CN101961504A (en) | 2011-02-02 |
| CN101961504B CN101961504B (en) | 2014-03-19 |
Family
ID=43514674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010253842.XA Expired - Fee Related CN101961504B (en) | 2010-08-13 | 2010-08-13 | Gel coating accessory capable of preventing spinal surgery cerebrospinal fluid leakage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101961504B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108159483A (en) * | 2018-02-06 | 2018-06-15 | 江西博恩锐尔生物科技有限公司 | Rapid surgical binds sealant |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249274A (en) * | 2008-04-01 | 2008-08-27 | 南京大学 | Preparation of bletilla striata polyose water gelatin of promoting wound healing and uses thereof |
| CN101524560A (en) * | 2007-03-05 | 2009-09-09 | 综合性外科公司 | Low swelling biocompatibility hydrogel |
| CN101745138A (en) * | 2010-01-09 | 2010-06-23 | 褚加冕 | Dressing preparation method of antibacterial amorphous hydrogel based on biological properties |
-
2010
- 2010-08-13 CN CN201010253842.XA patent/CN101961504B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101524560A (en) * | 2007-03-05 | 2009-09-09 | 综合性外科公司 | Low swelling biocompatibility hydrogel |
| CN101249274A (en) * | 2008-04-01 | 2008-08-27 | 南京大学 | Preparation of bletilla striata polyose water gelatin of promoting wound healing and uses thereof |
| CN101745138A (en) * | 2010-01-09 | 2010-06-23 | 褚加冕 | Dressing preparation method of antibacterial amorphous hydrogel based on biological properties |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108159483A (en) * | 2018-02-06 | 2018-06-15 | 江西博恩锐尔生物科技有限公司 | Rapid surgical binds sealant |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101961504B (en) | 2014-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101485897B (en) | Biocompatible hemostatic, antiblocking, healing-promoting and surgical wound-closing modified starch material | |
| US20240066179A1 (en) | Wound dressing comprising hyaluronic acid-calcium and polylysine and manufacturing method therefor | |
| CN101455857B (en) | Biocompatibility modified starch sponges | |
| CN103687631B (en) | Procoagulant peptides and their derivatives and uses therefor | |
| CN101497670B (en) | Biocompatibility pre-gelatinized modified starch and preparation thereof | |
| CN101121041A (en) | Denaturated starch absorbable hemostatic material and preparation method thereof | |
| Zheng et al. | Recent progress in surgical adhesives for biomedical applications | |
| US20190083676A1 (en) | Composite bioadhesive sealant | |
| KR101989054B1 (en) | Hemostatic agent and container containing the same | |
| US8673335B2 (en) | Methods and compositions for sealing and adhering biological tissues and medical uses thereof | |
| US11357883B1 (en) | Method for preparing absorbable haemostatic composition for body and haemostatic composition prepared thereby | |
| CN101961504B (en) | Gel coating accessory capable of preventing spinal surgery cerebrospinal fluid leakage | |
| ES2370458T3 (en) | COMBINATION FOR THE ADHERENCE OF BIOLOGICAL FABRICS. | |
| CN101954114B (en) | Gel coating accessory capable of preventing brain surgery cerebrospinal fluid leakage | |
| US20140235825A1 (en) | Biocompatible phase invertible proteinaceous compositions and methods for making and using the same | |
| US20230001048A1 (en) | Hemostatic paste and uses thereof | |
| Foster | Bioadhesives as surgical sealants: A Review | |
| CN101954113B (en) | Gel coating suite capable of preventing infection and leakage after eye surgery | |
| WO2019231763A1 (en) | Tissue adhesives and sealants using naturally derived aldehydes | |
| CN113365652A (en) | Hemostatic composition and container containing same | |
| US10660945B2 (en) | Flowable hemostatic gel composition and its methods of use | |
| US20230138347A1 (en) | Synthetic surgical hemostat | |
| Grimaldi et al. | Biotechnological Approaches to Hemostasis and Molecular Mechanisms of Wound Healing | |
| Shen et al. | Topical hemostatic agents in spinal surgery | |
| CN106075610A (en) | A kind of intervention punctures with hemostasis particle and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200619 Address after: 102600 room 304, gate 2, building 7, courtyard 5, Xingtai street, Daxing District, Beijing Patentee after: Wang Qingbin Address before: 100083 Beijing city Haidian District Wangzhuang Road No. 1, Tsinghua Tongfang Technology Plaza, B block 1009 Patentee before: BEIJING SURGK TECHNOLOGY Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140319 Termination date: 20210813 |